← All candidates
62 insider filings on record.
62 filings on record.
VSTMVerastem, Inc.
NasdaqCM · Healthcare · $742.62M
$7.32
-2.26% · Sep 15
62 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 35 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what VSTM ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$742.62M
Float
70.6M
78% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
8.5
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
57 more transactions on Pro →Context
Wall St
$15.13 avg target
+106.6% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26−$0.43 act+$0.04
Q4 '25−$0.46 act+$0.04
Q3 '25−$0.54 act+$0.07
Q2 '25−$0.63 act+$0.11
Coverage
Here’s What RBC Capital Has to Say About Verastem (VSTM)Insider Monkey · 07-03Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 TrialInsider Monkey · 06-30Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?Insider Monkey · 06-25Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid TumorsMT Newswires · 06-23
The file stays open
62 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice